EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VITRO TECHNIQUES

NIH GUIDE, Volume 23, Number 45, December 23, 1994



MAA AVAILABLE:  NCI-CN-55079-63



P.T. 34



Keywords:

  Chemoprevention 



National Cancer Institute



The Chemoprevention Branch, Division of Cancer Prevention and Control

(DCPC), National Cancer Institute (NCI), in its annual requirement to

seek new sources, is soliciting proposals for the Evaluation of

Chemopreventive Agents by In Vitro Techniques to increase the number

of Master Agreement (MA) Holders.  Current MA Holders for this

program are not required to submit a proposal.  This Master Agreement

Announcement (MAA) is issued to solicit MA Holders who have adequate

capabilities and technical expertise to screen and evaluate the

activity of chemopreventive agents in various in vitro assays of cell

transformation.  Agents with potential chemopreventive activity are

identified by epidemiologic surveys, initial laboratory

(experimental) findings, observations in the clinical setting, or

structural homology with agents having known chemopreventive

activity.  A rigorous and systematic evaluation of these candidate

agents is necessary before their efficacy can be examined in clinical

trials for cancer prevention.  In vitro screening and evaluation

techniques measuring the ability of these chemopreventive agents to

inhibit transformation provides a relatively rapid and efficient

means of qualifying these agents for further evaluation for the

prevention of cancer in humans.  Some of the agents to be used in

this project are potentially hazardous.  The in vitro systems may

involve the use of carcinogens, tumor cells, or tumor viruses.

Laboratory practices will be employed that will keep any element of

risk to personnel at an absolute minimum.  Where indicated, tissue

and compound handling must be performed in (at least) Class I laminar

flow cabinets, which must meet NIH specifications for work with these

agents.  The offeror will comply with NCI safety standards for

research involving chemical carcinogens (DHHS Publication No. NIH

76-900).  It will be required that the facilities have operating

tissue culture/cell biology and chemistry laboratories that are

suitable for using hazardous and/or carcinogenic materials as test

materials.  The contractor must have or be able to obtain all

equipment necessary to accomplish the studies including, but not

limited to, laminar flow hoods, CO2 incubators, equipment for

sterility testing, isotope counters, spectrophotometer, hazardous

chemical storage cabinets and refrigerators, equipment such as

microscopes and miscellaneous laboratory equipment.  The laboratory

must have or have access to appropriate terminal and computer

facilities and equipment for data collection and storage.  The period

of performance of the Master Agreement (MA) pool will be three years.

It is estimated that up to four Master Agreement Orders per year will

be issued to the Master Agreements.



INQUIRIES



Requests for this solicitation must be in writing and reference MAA

No. NCI-CN-55079-63.  The MAA will be available approximately January

9, 1995 and due approximately February 10, 1995.  Requests are to be

addressed to:



Ms. Tina Huyck

Research Contracts Branch, PCCS

National Cancer Institute

6120 Executive Boulevard  MSC 7226

Bethesda  MD  20892-7226

Telephone:  (301) 496-8603



.


Return to 1994 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.